Cargando…

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis

Three drug combinations, ipilimumab-nivolumab (Ipi-Nivo), pembrolizumab-axitinib (Pembro-Axi), and avelumab-axitinib (Ave-Axi), have received regulatory approval in the USA and Europe for the treatment of metastatic renal cell carcinoma with clear cell component (mRCC). However, no head-to-head comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elaidi, Reza, Phan, Letuan, Borchiellini, Delphine, Barthelemy, Philippe, Ravaud, Alain, Oudard, Stéphane, Vano, Yann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352474/ https://www.ncbi.nlm.nih.gov/pubmed/32599839 http://dx.doi.org/10.3390/cancers12061673

Ejemplares similares

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
por: Vano, Yann-Alexandre, et al.
Publicado: (2018)

Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
por: Jebali, M., et al.
Publicado: (2017)

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
por: Guillaume, Zoé, et al.
Publicado: (2022)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
por: Simonaggio, Audrey, et al.
Publicado: (2022)

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
por: Procureur, Adrien, et al.
Publicado: (2021)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
por: Dufies, Maeva, et al.
Publicado: (2018)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
por: Vaishampayan, Ulka, et al.
Publicado: (2019)

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
por: Bono, Petri, et al.
Publicado: (2016)

Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration
por: Bamias, A, et al.
Publicado: (2013)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
por: Lu, Xiaofan, et al.
Publicado: (2023)

Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)
por: Becht, Etienne, et al.
Publicado: (2015)

Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
por: Oudard, Stéphane, et al.
Publicado: (2016)

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
por: Dyar, Stephen, et al.
Publicado: (2011)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma
por: Czarnecka, Anna M., et al.
Publicado: (2019)

Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
por: Badran, Ahmed, et al.
Publicado: (2020)

Real-world efficacy of sequential nivolumab for metastatic renal cancer after first-line molecular targeting therapy
por: Obinata, Daisuke, et al.
Publicado: (2022)

Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma
por: Oudard, Stephane, et al.
Publicado: (2021)

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
por: Rong, Xuetong, et al.
Publicado: (2022)

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
por: Moscetti, Luca, et al.
Publicado: (2020)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence
por: Sun, Maxine, et al.
Publicado: (2014)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib
por: Kim, Myung Soo, et al.
Publicado: (2018)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
por: Bosma, Nicholas A., et al.
Publicado: (2022)

Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis
por: Qin, Suyang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_drf606uiaqjmnv4c3lroldlqhd